212 related articles for article (PubMed ID: 21072183)
1. p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.
Chow HY; Stepanova D; Koch J; Chernoff J
PLoS One; 2010 Nov; 5(11):e13791. PubMed ID: 21072183
[TBL] [Abstract][Full Text] [Related]
2. Group I p21-activated kinases (PAKs) promote tumor cell proliferation and survival through the AKT1 and Raf-MAPK pathways.
Menges CW; Sementino E; Talarchek J; Xu J; Chernoff J; Peterson JR; Testa JR
Mol Cancer Res; 2012 Sep; 10(9):1178-88. PubMed ID: 22798428
[TBL] [Abstract][Full Text] [Related]
3. PAK1 inhibition reduces tumor size and extends the lifespan of mice in a genetically engineered mouse model of Neurofibromatosis Type 2 (NF2).
Hawley E; Gehlhausen J; Karchugina S; Chow HY; Araiza-Olivera D; Radu M; Smith A; Burks C; Jiang L; Li X; Bessler W; Masters A; Edwards D; Burgin C; Jones D; Yates C; Clapp DW; Chernoff J; Park SJ
Hum Mol Genet; 2021 Aug; 30(17):1607-1617. PubMed ID: 34075397
[TBL] [Abstract][Full Text] [Related]
4. LIM domain kinases as potential therapeutic targets for neurofibromatosis type 2.
Petrilli A; Copik A; Posadas M; Chang LS; Welling DB; Giovannini M; Fernández-Valle C
Oncogene; 2014 Jul; 33(27):3571-82. PubMed ID: 23934191
[TBL] [Abstract][Full Text] [Related]
5. Group I Paks as therapeutic targets in NF2-deficient meningioma.
Chow HY; Dong B; Duron SG; Campbell DA; Ong CC; Hoeflich KP; Chang LS; Welling DB; Yang ZJ; Chernoff J
Oncotarget; 2015 Feb; 6(4):1981-94. PubMed ID: 25596744
[TBL] [Abstract][Full Text] [Related]
6. p21-activated kinase links Rac/Cdc42 signaling to merlin.
Xiao GH; Beeser A; Chernoff J; Testa JR
J Biol Chem; 2002 Jan; 277(2):883-6. PubMed ID: 11719502
[TBL] [Abstract][Full Text] [Related]
7. Validation of the p21-activated kinases as targets for inhibition in neurofibromatosis type 2.
Yi C; Wilker EW; Yaffe MB; Stemmer-Rachamimov A; Kissil JL
Cancer Res; 2008 Oct; 68(19):7932-7. PubMed ID: 18829550
[TBL] [Abstract][Full Text] [Related]
8. Merlin/NF2 regulates angiogenesis in schwannomas through a Rac1/semaphorin 3F-dependent mechanism.
Wong HK; Shimizu A; Kirkpatrick ND; Garkavtsev I; Chan AW; di Tomaso E; Klagsbrun M; Jain RK
Neoplasia; 2012 Feb; 14(2):84-94. PubMed ID: 22431917
[TBL] [Abstract][Full Text] [Related]
9. FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas.
Licciulli S; Maksimoska J; Zhou C; Troutman S; Kota S; Liu Q; Duron S; Campbell D; Chernoff J; Field J; Marmorstein R; Kissil JL
J Biol Chem; 2013 Oct; 288(40):29105-14. PubMed ID: 23960073
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous inhibition of PI3K and PAK in preclinical models of neurofibromatosis type 2-related schwannomatosis.
Nagel A; Huegel J; Petrilli A; Rosario R; Victoria B; Hardin HM; Fernandez-Valle C
Oncogene; 2024 Mar; 43(13):921-930. PubMed ID: 38336988
[TBL] [Abstract][Full Text] [Related]
11. The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors.
Zhou L; Lyons-Rimmer J; Ammoun S; Müller J; Lasonder E; Sharma V; Ercolano E; Hilton D; Taiwo I; Barczyk M; Hanemann CO
Oncogene; 2016 Jun; 35(26):3443-53. PubMed ID: 26549023
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of SIRT2 in merlin/NF2-mutant Schwann cells triggers necrosis.
Petrilli A; Bott M; Fernández-Valle C
Oncotarget; 2013 Dec; 4(12):2354-65. PubMed ID: 24259290
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of the NF2 tumor suppressor protein merlin in DU145 prostate cancer cells.
Horiguchi A; Zheng R; Shen R; Nanus DM
Prostate; 2008 Jun; 68(9):975-84. PubMed ID: 18361411
[TBL] [Abstract][Full Text] [Related]
14. Cellular transformation by a FERM domain mutant of the Nf2 tumor suppressor gene.
Johnson KC; Kissil JL; Fry JL; Jacks T
Oncogene; 2002 Sep; 21(39):5990-7. PubMed ID: 12203111
[TBL] [Abstract][Full Text] [Related]
15. Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1.
Kissil JL; Wilker EW; Johnson KC; Eckman MS; Yaffe MB; Jacks T
Mol Cell; 2003 Oct; 12(4):841-9. PubMed ID: 14580336
[TBL] [Abstract][Full Text] [Related]
16. Merlin, a regulator of Hippo signaling, regulates Wnt/β-catenin signaling.
Kim S; Jho EH
BMB Rep; 2016 Jul; 49(7):357-8. PubMed ID: 27345717
[TBL] [Abstract][Full Text] [Related]
17. A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor.
Hirokawa Y; Tikoo A; Huynh J; Utermark T; Hanemann CO; Giovannini M; Xiao GH; Testa JR; Wood J; Maruta H
Cancer J; 2004; 10(1):20-6. PubMed ID: 15000491
[TBL] [Abstract][Full Text] [Related]
18. The role of insulin-like growth factors signaling in merlin-deficient human schwannomas.
Ammoun S; Schmid MC; Ristic N; Zhou L; Hilton D; Ercolano E; Carroll C; Hanemann CO
Glia; 2012 Nov; 60(11):1721-33. PubMed ID: 22821509
[TBL] [Abstract][Full Text] [Related]
19. Neuregulin and laminin stimulate phosphorylation of the NF2 tumor suppressor in Schwann cells by distinct protein kinase A and p21-activated kinase-dependent pathways.
Thaxton C; Lopera J; Bott M; Fernandez-Valle C
Oncogene; 2008 Apr; 27(19):2705-15. PubMed ID: 17998937
[TBL] [Abstract][Full Text] [Related]
20. β1 integrin-dependent Rac/group I PAK signaling mediates YAP activation of Yes-associated protein 1 (YAP1) via NF2/merlin.
Sabra H; Brunner M; Mandati V; Wehrle-Haller B; Lallemand D; Ribba AS; Chevalier G; Guardiola P; Block MR; Bouvard D
J Biol Chem; 2017 Nov; 292(47):19179-19197. PubMed ID: 28972170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
